NASDAQ: CASI | 中文 | Contact Us

SEC Filings

SEC Filings

View all SEC filings through 2023-02-14 | CASI Pharmaceuticals
Please note that the above are links to www.sec.gov, a third-party web site. CASI Pharmaceuticals, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the information contained therein. Further, CASI Pharmaceuticals, Inc. takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.

Financial Reports

Date Form Description Web
April 26, 2023 20-F Form 20-F
February 14, 2023 DEF14A 2023 Proxy Statement
November 14, 2022 8-K 8-K
November 14, 2022 10-Q Quarterly Report
September 23, 2022 8-K Form 8-K
August 12, 2022 10-Q Quarterly Report
April 15, 2022 DEFA14A 2022 Definitive Additional Soliciting Materials
March 28, 2022 10-K Annual Report
November 12, 2021 10-Q Quarterly Report
August 12, 2021 10-Q Quarterly Report
June 07, 2021 DEFA14A 2021 Definitive Additional Soliciting Materials
May 13, 2021 10-Q Quarterly Report
May 10, 2021 10-K/A Annual Report Amendment No. 1
March 30, 2021 10-K Annual Report
November 9, 2020 10-Q Quarterly Report
August 10, 2020 10-Q Quarterly Report
May 11, 2020 10-Q Quarterly Report
March 16, 2020 10-K Annual Report
November 12, 2019 10-Q Quarterly Report
August 09, 2019 10-Q Quarterly Report
May 15, 2019 10-Q Quarterly Report
March 29, 2019 10-K Annual Report
November 14, 2018 10-Q Quarterly Report
August 14, 2018 10-Q Quarterly Report
May 15, 2018 10-Q Quarterly Report
March 29, 2018 10-K Annual Report
November 14, 2017 10-Q Quarterly Report
August 14, 2017 10-Q Quarterly Report
May 15, 2017 10-Q Quarterly Report
March 31, 2017 10-K Annual Report
November 14, 2016 10-Q Quarterly Report
August 15, 2016 10-Q Quarterly Report
May 13, 2016 10-Q Quarterly Report

The Company will provide its shareholders, upon request, a hard copy of the Company’s annual report on Form 20-F free of charge.

About Us

CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.

Learn More